JPMorgan analyst Jessica Fye lowered the firm’s price target on Alkermes to $31 from $32 and keeps a Neutral rating on the shares. The analyst updated the company’s model following a CEO conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid
- Alkermes initiated with a Buy at TD Cowen
- Alkermes orexin 2 receptor story ignored by investors, says Jefferies
- Alkermes presents data from phase 1b study of ALKS 2680
- Alkermes Shareholders Approve Board Changes and Stock Plan